Related references
Note: Only part of the references are listed.Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis
Toshifumi Tada et al.
LIVER INTERNATIONAL (2016)
Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
Tushar Garimella et al.
ANTIVIRAL THERAPY (2015)
The association of hepatitis C virus infection with the prognosis of chronic hemodialysis patients: A retrospective study of 3,064 patients between 1999 and 2010
Junko Tanaka et al.
JOURNAL OF MEDICAL VIROLOGY (2015)
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
David Roth et al.
LANCET (2015)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors
Yoshihito Uchida et al.
PLOS ONE (2014)
Pegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis A Randomized Trial
Chen-Hua Liu et al.
ANNALS OF INTERNAL MEDICINE (2013)
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study
Eiichi Ogawa et al.
JOURNAL OF HEPATOLOGY (2013)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study
Mei-Hsuan Lee et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy
P. Deltenre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Treatment of hepatitis C virus infection in patients with end-stage renal disease
Chen-Hua Liu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus
Amit G. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C
Shuichi Kaneko et al.
HEPATOLOGY RESEARCH (2010)
Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load
Hidenori Toyoda et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
An Early Viral Response to Standard Interferon-Alpha Identifies Resistance to Combination Therapy With Peginterferon and Ribavirin in Patients Infected by HCV Genotype 1
Hidenori Toyoda et al.
JOURNAL OF MEDICAL VIROLOGY (2010)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Treatment of Chronic Hepatitis C in Hemodialysis Patients
Marina Berenguer
HEPATOLOGY (2008)
Hepatitis C virus and kidney disease
Paul Martin et al.
JOURNAL OF HEPATOLOGY (2008)
Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load
Kenji Fujiwara et al.
HEPATOLOGY RESEARCH (2007)
Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia
EPA Lopes et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients
F Fabrizi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Hepatitis C infection and the patient with end-stage renal disease
F Fabrizi et al.
HEPATOLOGY (2002)
Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients
M Espinosa et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Reappraisal of biochemical hepatitis C activity in hemodialysis patients
N Yuki et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2000)
Share Paper
